Evidence map›Paper›PMID 18245462›Full record

ArticleCancer research2008

A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.

Bharathi Laxman, David S Morris, Jianjun Yu, Javed Siddiqui, Jie Cao, Rohit Mehra, Robert J Lonigro, Alex Tsodikov, John T Wei, Scott A Tomlins and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 166 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
166citing papers in PubMed, 5 pooled it
36.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

166 citing papers in PubMed, 5 syntheses or guidelines pooled it, 405 citations in OpenAlex.

  1. Pooled it
  2. Evaluation of the TMPRSS2:ERG fusion for the detection of prostate cancer: a systematic review and meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis.International braz j urol : official journal of the Brazilian Society of Urology
    Pooled it
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. GOLM1 as a Potential Therapeutic Target Modulates B7-H3 Secretion to Drive Ovarian Cancer Metastasis.Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  17. Article
  18. Review
  19. Article
  20. Article

106 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Bharathi LaxmanMichigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109-0602, USA.
David S Morris
Jianjun Yu
Javed Siddiqui
Jie Cao
Rohit Mehra
Robert J Lonigro
Alex Tsodikov
John T Wei
Scott A Tomlins
Arul M Chinnaiyan
Center for Translational Molecular Medicine · NLMichigan Center for Translational Pathology · US

Funding

VACCINIA PSA FOR ANDROGEN-MODULATED POST-SURGICAL RECURRENCE OF PROSTATE CANCERP50CA069568 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COONEY, KATHLEEN A · 1995 to 2013
$31.3M
Nation Center- Integrative Biomedical Informatics(RMI)U54DA021519 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ATHEY, BRIAN DAVID · 2005 to 2010
$21.3M
Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas SouthwesternU01CA113913 · NCI · EMORY UNIVERSITY · PI Martin G. Sanda · 2005 to 2026
$16.4M
Epitomic Biomarkers of Prostate CancerU01CA111275 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M, RUBIN, MARK A. · 2004 to 2015
$6.8M
Survival Effects of Prostate Cancer SurveillanceU01CA097414 · NCI · UNIVERSITY OF UTAH · PI TSODIKOV, ALEXANDER · 2002 to 2009
$1.4M
Molecular Changes Associated with PCa bone metastasesR01CA102872 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PIENTA, KENNETH J. · 2003 to 2006
$1.3M
NCI NIH HHS P50 CA069568NCI NIH HHS P50CA69568NCI NIH HHS R01 CA102872NCI NIH HHS U01 CA097414NCI NIH HHS U01 CA111275NCI NIH HHS U01 CA113913NCI NIH HHS UO1 CA111275-01NCI NIH HHS UO1 CA113913NIDA NIH HHS U54 DA021519NIDA NIH HHS U54 DA021519-01A1
6 · The paper itself

Abstract

Although prostate-specific antigen (PSA) serum level is currently the standard of care for prostate cancer screening in the United States, it lacks ideal specificity and additional biomarkers are needed to supplement or potentially replace serum PSA testing. Emerging evidence suggests that monitoring the noncoding RNA transcript PCA3 in urine may be useful in detecting prostate cancer in patients with elevated PSA levels. Here, we show that a multiplex panel of urine transcripts outperforms PCA3 transcript alone for the detection of prostate cancer. We measured the expression of seven putative prostate cancer biomarkers, including PCA3, in sedimented urine using quantitative PCR on a cohort of 234 patients presenting for biopsy or radical prostatectomy. By univariate analysis, we found that increased GOLPH2, SPINK1, and PCA3 transcript expression and TMPRSS2:ERG fusion status were significant predictors of prostate cancer. Multivariate regression analysis showed that a multiplexed model, including these biomarkers, outperformed serum PSA or PCA3 alone in detecting prostate cancer. The area under the receiver-operating characteristic curve was 0.758 for the multiplexed model versus 0.662 for PCA3 alone (P = 0.003). The sensitivity and specificity for the multiplexed model were 65.9% and 76.0%, respectively, and the positive and negative predictive values were 79.8% and 60.8%, respectively. Taken together, these results provide the framework for the development of highly optimized, multiplex urine biomarker tests for more accurate detection of prostate cancer.

Indexed as

Antigens, NeoplasmBiomarkers, TumorCarrier ProteinsDNA-Binding ProteinsDNA, ComplementaryHumansMaleMembrane ProteinsOncogene Proteins, FusionPeptidesPolymerase Chain ReactionProstatic NeoplasmsRacemases and EpimerasesRNA, NeoplasmTrans-ActivatorsTranscriptional Regulator ERGalpha-methylacyl-CoA racemaseAntigens, NeoplasmBiomarkers, TumorCarrier ProteinsDNA-Binding ProteinsDNA, ComplementaryERG protein, humanGOLM1 protein, humanMembrane ProteinsOncogene Proteins, FusionPeptidesprostate cancer antigen 3, humanRacemases and EpimerasesRNA, NeoplasmSPINK1 protein, humanTFF3 protein, humanTMPRSS2-ERG fusion protein, humanTrans-ActivatorsTranscriptional Regulator ERGTrefoil Factor-3Trypsin Inhibitor, Kazal Pancreatic

Identifiers

PMID18245462
PMCPMC2998181
OpenAlexW2147010946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.